Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* female participants, \>=18 years of age;~* stage III, or inflammatory breast cancer;~* estrogen receptor/progesterone receptor (ER/PgR) positive or negative and human epidermal growth factor receptor 2 (HER-2) negative;~* normal left ventricular ejection fraction (LVEF).~Exclusion Criteria:~* previous chemotherapy/endocrine therapy;~* evidence of distant metastatic disease;~* other primary tumors in last 5 years (except for adequately treated cancer in situ of the cervix, or basal cell skin cancer);~* chronic daily treatment with \>325 milligram per day (mg/day) aspirin, or \>75mg/day clopidogrel.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Type: EXPERIMENTAL): Participants will receive FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).